Related Experiment Video

Updated: May 6, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.4K

Ubiquitin E3 ligase SCF(β-TRCP) regulates TRIB2 stability in liver cancer cells

Yongxia Qiao1, Yue Zhang, Jiayi Wang

  • 1School of Public Health, Shanghai Jiaotong University, Shanghai 200025, China.

Biochemical and Biophysical Research Communications
|November 12, 2013
PubMed

Insights

Tribbles homolog 2 (TRIB2) protein stability in liver cancer is also regulated by the SCF(β-TRCP) ubiquitin ligase. This finding identifies new therapeutic targets for TRIB2-dependent liver cancers.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Tribbles homolog 2 (TRIB2) is crucial for liver cancer cell survival and transformation.
  • TRIB2 stability in liver cancer is linked to impaired ubiquitination by Smurf1.
  • The complete mechanisms regulating TRIB2 degradation remain incompletely understood.

Purpose of the Study:

  • To investigate additional ubiquitin E3 ligases controlling TRIB2 stability.
  • To elucidate the role of SCF(β-TRCP) in TRIB2 ubiquitination and degradation.
  • To explore potential therapeutic strategies for TRIB2-dependent liver cancer.

Main Methods:

  • Depletion of Cullin1 and β-TRCP using knockdown techniques.
  • Assessment of TRIB2 protein expression levels.
  • Measurement of TRIB2 protein half-life and ubiquitination status.
  • Analysis of TRIB2 interaction with SCF(β-TRCP) via the TRIB2 Degradation Domain (TDD).

Main Results:

  • Depletion of Cullin1 or β-TRCP leads to increased TRIB2 protein levels.
  • Knockdown of β-TRCP increases TRIB2 half-life and decreases its ubiquitination.
  • β-TRCP targets TRIB2 for degradation through its N-terminal TDD, similar to Smurf1.
  • TRIB2 is identified as a substrate of the SCF(β-TRCP) ubiquitin ligase complex.

Conclusions:

  • SCF(β-TRCP) plays a significant role in regulating TRIB2 protein stability and degradation.
  • The findings expand the known regulatory network of TRIB2.
  • Targeting the SCF(β-TRCP)-TRIB2 interaction may offer a novel therapeutic approach for liver cancer.
Keywords:
CHXCullin1HCCHepatocellular carcinoma (HCC)IFProtein stabilitySCF complexSKP1–cullin–F-box complexTDD domainTRIB2TRIB2 degradation domainUbiquitinationbeta-transducin repeat containing E3 ubiquitin protein ligasecycloheximidehepatocellular carcinomaimmunofluorescencetribbles homolog 2β-TRCP

More Related Videos

In Vitro Analysis of E3 Ubiquitin Ligase Function06:06

In Vitro Analysis of E3 Ubiquitin Ligase Function

Published on: May 14, 2021

5.3K
Assaying Proteasomal Degradation in a Cell-free System in Plants07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

13.9K

Related Concept Videos

Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
6.6K
Regulated Protein Degradation02:58

Regulated Protein Degradation

2.5K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K